Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
CINC
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q4.21
N/A
-15.71
vs -0.16
Q1.22
N/A
-0.50
vs -0.16
Q2.22
N/A
-0.56
vs -0.19
Q3.22
N/A
-0.51
vs -0.25
Sales Growth
YoY
Current
Estimates
Q4.21
NA
NA vs NA
Q1.22
NA
NA vs NA
Q2.22
NA
NA vs NA
Q3.22
NA
NA vs NA
Return on Equity
QoQ
Q1.21
NA
NA
vs 0.21
Q2.21
NA
NA
vs NA
Q3.21
+20%
0.2
vs NA
Q4.21
+52%
0.52
vs 0.2
Q1.22
-6%
-0.06
vs 0.52
Q2.22
-7%
-0.07
vs -0.06
Q3.22
-4%
-0.04
vs -0.07
Institutionnal Ownership
QoQ
Q1.22
53
53
vs NA
NA
Q2.22
57
57
vs 53
8%
Q3.22
89
89
vs 57
56%
Q4.22
113
113
vs 89
27%
reuters.com
2 hours ago
barrons.com
4 hours ago
proactiveinvestors.co.uk
7 hours ago
marketbeat.com
9 hours ago
investorplace.com
10 hours ago
prnewswire.com
22 hours ago
Quote Panel
Key Metrics
Forecast
No Data Available
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
0.00(-100.00%)
Number of analyst
0
Last analyst upgrade/downgrade
Barclays
downgradePrevious: Overweight
2023-01-12
Now: Equal-Weight
Barclays
initialisePrevious: Not converted
2022-12-07
Now: Overweight
Morgan Stanley
downgradePrevious: Not converted
2022-11-29
Now: Equal-Weight
Oppenheimer
downgradePrevious: Outperform
2022-11-28
Now: Perform
Relative Strength
CINC
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. CinCor Pharma, Inc. has a license agreement with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.
NASDAQ
Unprofitable
Unprofitable
Relative Strenght
86
Volume Buzz
-100%
Earning Acce
Yes
Dist 52w H.
33%Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How CINC compares to sector?
CINC
-20x